Startup financier Accelerator Life Science Partners formed two new advisory panels to guide its business decisions, while expanding into San Diego.
Pfizer expanded its work with XtalPi to develop an AI platform to model small-molecule drugs as part of its discovery and development efforts.
For children diagnosed with rare diseases, traditional drug development timelines are not good enough. Collaborative partnerships are imperative to accelerate…
Worldwide Clinical Trials and Datavant are collaborating on a neurodegenerative disease pilot study incorporating clinical data with real-world evidence.
Charles River Laboratories and The Michael J. Fox Foundation for Parkinson’s Research have extended their collaboration.
UCB and Science 37 will work to bring clinical trials out of traditional sites and into the home, using telemedicine and outcomes reported online.
Bristol-Myers Squibb and Flatiron Health signed a three-year agreement, planning to form an advisory board on real-world evidence in drug submissions.
Charles River Labs is expanding its services into the early discovery setting, offering high-speed pharmacokinetics screening of compounds’ underlying biology.
RxCelerate has absorbed the services and staff of Total Scientific, a CRO focused in bioanalysis, protein assays and gene-phenotype association.
WuXi AppTec’s contract development and manufacturing subsidiary plans to build a new R&D center in Shanghai, next door to its production plant.
Most of the top noncommercial funders of clinical trials have no policies that mandate the eventual reporting of study results, Alltrials says.